Comparing eczema treatments for moderate-to-severe disease
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study compares two types of eczema treatments—upadacitinib and biologics—to see how well they help adults with moderate-to-severe atopic dermatitis achieve minimal disease activity. It may help you understand which treatment option could work best for your eczema.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a doctor-confirmed diagnosis of moderate-to-severe atopic dermatitis (eczema).
- Your eczema symptoms started at least 1 year ago.
- You are either new to biologic treatments or have used a biologic for eczema within the past 2 years.
- You are about to start upadacitinib or an approved biologic for eczema, as prescribed by your doctor.
- You are willing to fill out questionnaires about your health and eczema.
- You have not used the specific eczema treatment being studied before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This study compares a new injectable medicine (IBI3027) to an approved one (Dupilumab) for people with moderate-to-severe eczema. If you join, you'll receive one of the two treatments to see if the new one works as well for reducing itching and skin symptoms.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
This study tests a new medication called IBI3033 for people with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams alone. The goal is to see if this drug can safely reduce itching, inflammation, and affected skin area.
This study follows adults with moderate to severe eczema who are eligible for or already taking systemic (pill or injection) medicines. It does not test any new drug—it simply tracks how eczema is managed in real life, which may help improve future care.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.